StockNews.com Initiates Coverage on Aethlon Medical (NASDAQ:AEMD)

Stock analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a research note on Friday.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $0.40 on Friday. The company has a market cap of $5.57 million, a price-to-earnings ratio of -0.14 and a beta of 1.74. The firm has a 50 day simple moving average of $0.40 and a 200 day simple moving average of $0.49. Aethlon Medical has a one year low of $0.24 and a one year high of $2.35.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same quarter last year, the firm earned ($1.30) EPS. As a group, analysts expect that Aethlon Medical will post -1.1 EPS for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.